Alcon has agreed to acquire LumiThera and its FDA-cleared Valeda system, a light-based therapy for dry age-related macular degeneration (AMD). The Valeda system uses photobiomodulation to stimulate retinal cell mitochondria, offering the first US treatment for dry AMD. FDA data shows it can improve vision by about one line on an eye chart after two years of treatments.
